No-x-sha rectal suppositories 0.04 g blister No. 10

However, it is prescribed for therapeutic purposes for:

No-x-sha is also recommended as an adjunctive treatment for:

composition

active ingredient: drotaverine hydrochloride;

1 suppository contains drotaverine hydrochloride in terms of dry matter 0.04 g (40 mg);

excipient: solid fat.

Drotaverine, an isoquinoline derivative, exhibits an antispasmodic effect on smooth muscles by inhibiting the action of the enzyme phosphodiesterase IV (PDE IV), which leads to an increase in the concentration of cAMP and, due to the inactivation of myosin light link kinase (MLCK), leads to relaxation of smooth muscles.

Drotaverine is effective in smooth muscle spasms of both nervous and muscular origin. Drotaverine acts on the smooth muscles of the gastrointestinal, biliary, genitourinary and vascular systems, regardless of the type of their autonomic innervation.

It increases blood circulation in tissues due to its ability to dilate blood vessels.

Contraindication

Hypersensitivity to drotaverine or any component of the drug. Severe hepatic, renal or heart failure (small cardiac output syndrome).

Method of administration and doses

Before using the suppository, you must:

The drug is intended for rectal use.

Dosage for adults and children over 12 years old - 1 suppository 2 times a day. The duration of treatment is determined individually by the doctor.

Overdose

With a significant overdose of drotaverine, cardiac rhythm and conduction disturbances were observed, including complete blockade of the bundle of His and cardiac arrest, which can be fatal.

In case of overdose, the patient should be under close medical supervision and receive symptomatic treatment.

adverse reactions

Side effects that were observed during clinical trials and were possibly caused by drotaverine were distributed across organ systems.

On the part of the immune system: allergic reactions, including angioedema, urticaria, rash, itching, redness of the skin, fever, chills, increased body temperature, weakness.

Cardiovascular system: palpitations, hypotension.

From the nervous system: headache, dizziness, insomnia.

Gastrointestinal: nausea, constipation, vomiting.

Application features

Use during pregnancy or breastfeeding

Pregnancy. As shown by the results of clinical studies and animal studies, the use of drotaverine did not cause any signs of any direct or indirect effect on pregnancy, embryonic development, childbirth or postnatal development. However, caution should be exercised when prescribing the drug to pregnant women.

Breastfeeding. Due to the lack of data, the use of the drug during breastfeeding is not recommended.

children

The drug should not be used to treat children under 12 years of age.

Ability to influence reaction speed when driving vehicles or other mechanisms

If patients experience dizziness after using the drug, they should avoid potentially dangerous activities, such as driving a car and performing work that requires increased attention.

Interaction with other medicinal products and other types of interactions

Phosphodiesterase inhibitors, such as papaverine, reduce the antiparkinsonian effect of levodopa. Caution should be exercised when No-X-sha ® is used concomitantly with levodopa, as the antiparkinsonian effect of the latter is reduced and rigidity and tremor are increased.

Storage conditions

Store out of the reach of children in the original packaging at a temperature not exceeding 25 °C.

Shelf life - 2 years.